dr amol kotalwar | selection of 1st line immunotherapy in pdl1 negative & non driver mutations
Published 1 year ago • 173 plays • Length 9:42Download video MP4
Download video MP3
Similar videos
-
11:28
dr gaurang modi | slection of 1st line immunotherapy in pdl1 negative and non driver mutations mnscl
-
8:40
dr vikas | should we recommend io first line in pdl1 negative patients advanced nsclc
-
14:12
dr navneet singh | selection of 1st line immunotherapy pdl1 50% & 1% in nsclc
-
15:04
dr amol akhade | comparative effectiveness and safety of standard dose and low dose pembrolizumab
-
33:14
case based viva | moderator: dr murad lala | 6th master class in lung cancer | crsf
-
1:00
7 things to know about immunotherapy
-
1:24
kd033, a pdl1-1l15 bispecific molecule for the treatment of cancer
-
1:33:59
revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
1:16
explaining immunotherapy, pd-l1 and pd-1
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
7:21
comparative efficacy of chemoimmunotherapy v immunotherapy for 1st-line treatment of advanced nsclc
-
2:00
immunotherapy: another weapon against cancer | afp
-
1:03
dr. costa on biomarkers beyond pd-l1 for immunotherapy in nsclc
-
45:10
cancer immunotherapy workshop 2021 – moderated open discussion: immune effects by tumor types
-
2:34
immunology, immunotherapy, and developments in cancer treatment
-
3:46
immunotherapy as first-line treatment